X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1062) 1062
index medicus (1012) 1012
proto-oncogene proteins b-raf - genetics (916) 916
mutation (703) 703
female (614) 614
male (603) 603
middle aged (520) 520
cancer (505) 505
oncology (458) 458
adult (444) 444
braf (442) 442
aged (388) 388
braf mutation (384) 384
thyroid neoplasms - genetics (375) 375
melanoma (369) 369
braf v600e mutation (287) 287
gene mutations (269) 269
genetic aspects (267) 267
thyroid neoplasms - pathology (266) 266
pathology (265) 265
prognosis (256) 256
v600e mutation (248) 248
carcinoma (229) 229
tumors (228) 228
proto-oncogene proteins b-raf - metabolism (215) 215
immunohistochemistry (207) 207
vemurafenib (203) 203
thyroid cancer (200) 200
thyroid cancer, papillary (195) 195
melanoma - genetics (192) 192
young adult (175) 175
dna mutational analysis (172) 172
aged, 80 and over (170) 170
b-raf (170) 170
braf v600e (169) 169
adolescent (165) 165
proto-oncogene proteins b-raf - antagonists & inhibitors (164) 164
carcinoma - genetics (156) 156
carcinoma, papillary (152) 152
endocrinology & metabolism (152) 152
carcinoma, papillary - genetics (151) 151
metastasis (151) 151
metastatic melanoma (151) 151
neoplasms (150) 150
analysis (148) 148
diagnosis (148) 148
animals (146) 146
cell line, tumor (141) 141
expression (132) 132
retrospective studies (132) 132
mutation - genetics (131) 131
article (127) 127
papillary thyroid carcinoma (127) 127
biomarkers, tumor - genetics (125) 125
v600e (125) 125
research (123) 123
survival (123) 123
melanoma - drug therapy (122) 122
melanoma - pathology (120) 120
endocrine system diseases (117) 117
kinases (116) 116
association (115) 115
surgery (113) 113
cell biology (111) 111
colorectal cancer (111) 111
care and treatment (110) 110
health aspects (108) 108
mutations (106) 106
neoplasm staging (106) 106
activation (105) 105
carcinoma - pathology (100) 100
colorectal neoplasms - genetics (100) 100
gene (98) 98
abridged index medicus (97) 97
carcinoma, papillary - pathology (97) 97
child (97) 97
digestive system diseases (95) 95
pathway (93) 93
polymerase chain reaction (93) 93
skin neoplasms - genetics (93) 93
thyroid neoplasms - metabolism (92) 92
antineoplastic agents - therapeutic use (90) 90
medicine & public health (88) 88
thyroid neoplasms - diagnosis (88) 88
protein kinase inhibitors - pharmacology (87) 87
microsatellite instability (86) 86
mice (85) 85
treatment outcome (85) 85
nodules (81) 81
thyroid (79) 79
patients (76) 76
high prevalence (74) 74
risk factors (74) 74
sensitivity and specificity (74) 74
protein kinase inhibitors - therapeutic use (73) 73
resistance (73) 73
biopsy, fine-needle (69) 69
dabrafenib (69) 69
acquired-resistance (68) 68
malignant-melanoma (67) 67
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annual Review of Medicine, ISSN 0066-4219, 1/2016, Volume 67, Issue 1, pp. 29 - 43
Journal Article
BIOCHEMICAL PHARMACOLOGY, ISSN 0006-2952, 05/2017, Volume 132, pp. 63 - 76
B-Raf kinase is the key point in a main branch of mitogen-activated protein kinase pathways and some of its mutations, such as the V600E mutation, lead to the... 
DESIGN | Virtual simulation | DRUG DISCOVERY | FBDD strategy | BRAF INHIBITORS | BRAF(V600E) INHIBITOR | ANTITUMOR-ACTIVITY | CANCER-THERAPY | Chemotherapy | MELANOMA | B-Raf inhibitor | RAF INHIBITORS | PHARMACOLOGY & PHARMACY | DERIVATIVES | Xenograft model | VEMURAFENIB
Journal Article
Journal Article
Journal Article
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ISSN 0960-894X, 09/2011, Volume 21, Issue 18, pp. 5533 - 5537
Structure-activity relationships around a novel series of B-Raf(V600E) inhibitors are reported. The enzymatic and cellular potencies of inhibitors derived from... 
ACTIVATION | DESIGN | CHEMISTRY, MEDICINAL | Pyrrolopyridine | CHEMISTRY, ORGANIC | KINASE INHIBITORS | BRAF | Pyrazolopyridine | DISCOVERY | POTENT | B-Raf(V600E) | PATHWAY | Structure-activity relationship | B-RAF | MUTATIONS
Journal Article
by Wang, PF and Wang, ZF and Qiu, HY and Huang, Y and Hu, HM and Wang, ZC and Zhu, HL
CHEMMEDCHEM, ISSN 1860-7179, 12/2018, Volume 13, Issue 23, pp. 2558 - 2566
The mitogen-activated protein kinase (MAPK) pathway plays a vital role in signal transduction networks. Severe diseases may be triggered if it is disturbed by... 
rational drug design | CHEMISTRY, MEDICINAL | mouse xenografts | molecular optimization | SHIKONIN DERIVATIVES | RAF KINASE | BRAF V600E MUTATION | SORAFENIB | CANCER | DISCOVERY | DIHYDROPYRAZOLE SULFONAMIDE | PHARMACOLOGY & PHARMACY | B-RAF | in silico studies | ASSOCIATION | B-Raf inhibitors | VEMURAFENIB
Journal Article
MOLECULAR PHARMACEUTICS, ISSN 1543-8384, 11/2012, Volume 9, Issue 11, pp. 3236 - 3245
Vemurafenib (PLX4032) is a novel tyrosine kinase inhibitor that has clinical efficacy against metastatic melanoma harboring a BRAF(V600E) mutation. We aimed to... 
blood-brain barrier | DRUG | MEDICINE, RESEARCH & EXPERIMENTAL | B-RAF(V600E) | METASTASES | BARRIER | vemurafenib | melanoma | oral availability | COOPERATION | TRANSPORT | EFFLUX | elacridar | MUTATION | PHARMACOLOGY & PHARMACY | ABC transporters | brain metastasis | ACCUMULATION | FLAVOPIRIDOL
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 07/2014, Volume 12, Issue 1, pp. 216 - 216
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2016, Volume 78, Issue 2, pp. 419 - 426
Journal Article
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0223-5234, 06/2016, Volume 115, pp. 201 - 216
Journal Article